Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
INTC CEO Lip-Bu Tan filed on August 14 that he bought $10M of Intel stock in the open market on August 11. That is a significant personal bet at a company fighting to rebuild its manufacturing edge. The trade was discretionary, not under a 10b5-1 plan, and Tan took the position just weeks into a wider recovery attempt.
BSX CEO Michael Mahoney followed a similar script. He filed an $9M open-market purchase on August 5, trading on August 3. Boston Scientific has been expanding aggressively in structural heart and electrophysiology. A chairman-level buy of that size outside a pre-arranged plan carries weight.
On the selling side, CPAY CEO Ron Clarke filed a $121M sale on August 25. AMD CEO Lisa Su disclosed an $80M sale on August 18. Neither company disclosed a 10b5-1 plan flag, though sales of this scale at large-cap names often reflect portfolio management rather than negative conviction.
Two ET insiders bought a combined $21.5M of Energy Transfer units between August 7 and 19, a cluster that rarely appears without an internal view on distribution sustainability.
APH CEO Richard Norwitt sold $80.8M on July 31. Amphenol's stock has run hard on AI infrastructure demand, making the timing understandable even if the signal is muted.
The most eye-catching non-US move: Fast Retailing founder Tadashi Yanai filed a $1.57B sale on August 21. At that scale, it is almost certainly estate planning, not a market call.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
